1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Companion Cancer Diagnostics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Breast Cancer
1.2.3 Lung Cancer
1.2.4 Colorectal Cancer
1.2.5 Melanoma
1.2.6 Gastric Cancer
1.3 Market by Application
1.3.1 Global Companion Cancer Diagnostics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Pharmaceutical & Biopharmaceutical Companies
1.3.3 Reference Laboratories
1.3.4 CROs
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Companion Cancer Diagnostics Market Perspective (2017-2028)
2.2 Companion Cancer Diagnostics Growth Trends by Region
2.2.1 Companion Cancer Diagnostics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Companion Cancer Diagnostics Historic Market Size by Region (2017-2022)
2.2.3 Companion Cancer Diagnostics Forecasted Market Size by Region (2023-2028)
2.3 Companion Cancer Diagnostics Market Dynamics
2.3.1 Companion Cancer Diagnostics Industry Trends
2.3.2 Companion Cancer Diagnostics Market Drivers
2.3.3 Companion Cancer Diagnostics Market Challenges
2.3.4 Companion Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Companion Cancer Diagnostics Players by Revenue
3.1.1 Global Top Companion Cancer Diagnostics Players by Revenue (2017-2022)
3.1.2 Global Companion Cancer Diagnostics Revenue Market Share by Players (2017-2022)
3.2 Global Companion Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Companion Cancer Diagnostics Revenue
3.4 Global Companion Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Companion Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Companion Cancer Diagnostics Revenue in 2021
3.5 Companion Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Companion Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Companion Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Companion Cancer Diagnostics Breakdown Data by Type
4.1 Global Companion Cancer Diagnostics Historic Market Size by Type (2017-2022)
4.2 Global Companion Cancer Diagnostics Forecasted Market Size by Type (2023-2028)
5 Companion Cancer Diagnostics Breakdown Data by Application
5.1 Global Companion Cancer Diagnostics Historic Market Size by Application (2017-2022)
5.2 Global Companion Cancer Diagnostics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Companion Cancer Diagnostics Market Size (2017-2028)
6.2 North America Companion Cancer Diagnostics Market Size by Type
6.2.1 North America Companion Cancer Diagnostics Market Size by Type (2017-2022)
6.2.2 North America Companion Cancer Diagnostics Market Size by Type (2023-2028)
6.2.3 North America Companion Cancer Diagnostics Market Share by Type (2017-2028)
6.3 North America Companion Cancer Diagnostics Market Size by Application
6.3.1 North America Companion Cancer Diagnostics Market Size by Application (2017-2022)
6.3.2 North America Companion Cancer Diagnostics Market Size by Application (2023-2028)
6.3.3 North America Companion Cancer Diagnostics Market Share by Application (2017-2028)
6.4 North America Companion Cancer Diagnostics Market Size by Country
6.4.1 North America Companion Cancer Diagnostics Market Size by Country (2017-2022)
6.4.2 North America Companion Cancer Diagnostics Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Companion Cancer Diagnostics Market Size (2017-2028)
7.2 Europe Companion Cancer Diagnostics Market Size by Type
7.2.1 Europe Companion Cancer Diagnostics Market Size by Type (2017-2022)
7.2.2 Europe Companion Cancer Diagnostics Market Size by Type (2023-2028)
7.2.3 Europe Companion Cancer Diagnostics Market Share by Type (2017-2028)
7.3 Europe Companion Cancer Diagnostics Market Size by Application
7.3.1 Europe Companion Cancer Diagnostics Market Size by Application (2017-2022)
7.3.2 Europe Companion Cancer Diagnostics Market Size by Application (2023-2028)
7.3.3 Europe Companion Cancer Diagnostics Market Share by Application (2017-2028)
7.4 Europe Companion Cancer Diagnostics Market Size by Country
7.4.1 Europe Companion Cancer Diagnostics Market Size by Country (2017-2022)
7.4.2 Europe Companion Cancer Diagnostics Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Companion Cancer Diagnostics Market Size (2017-2028)
8.2 Asia-Pacific Companion Cancer Diagnostics Market Size by Type
8.2.1 Asia-Pacific Companion Cancer Diagnostics Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Companion Cancer Diagnostics Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Companion Cancer Diagnostics Market Share by Type (2017-2028)
8.3 Asia-Pacific Companion Cancer Diagnostics Market Size by Application
8.3.1 Asia-Pacific Companion Cancer Diagnostics Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Companion Cancer Diagnostics Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Companion Cancer Diagnostics Market Share by Application (2017-2028)
8.4 Asia-Pacific Companion Cancer Diagnostics Market Size by Region
8.4.1 Asia-Pacific Companion Cancer Diagnostics Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Companion Cancer Diagnostics Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Companion Cancer Diagnostics Market Size (2017-2028)
9.2 Latin America Companion Cancer Diagnostics Market Size by Type
9.2.1 Latin America Companion Cancer Diagnostics Market Size by Type (2017-2022)
9.2.2 Latin America Companion Cancer Diagnostics Market Size by Type (2023-2028)
9.2.3 Latin America Companion Cancer Diagnostics Market Share by Type (2017-2028)
9.3 Latin America Companion Cancer Diagnostics Market Size by Application
9.3.1 Latin America Companion Cancer Diagnostics Market Size by Application (2017-2022)
9.3.2 Latin America Companion Cancer Diagnostics Market Size by Application (2023-2028)
9.3.3 Latin America Companion Cancer Diagnostics Market Share by Application (2017-2028)
9.4 Latin America Companion Cancer Diagnostics Market Size by Country
9.4.1 Latin America Companion Cancer Diagnostics Market Size by Country (2017-2022)
9.4.2 Latin America Companion Cancer Diagnostics Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Companion Cancer Diagnostics Market Size (2017-2028)
10.2 Middle East & Africa Companion Cancer Diagnostics Market Size by Type
10.2.1 Middle East & Africa Companion Cancer Diagnostics Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Companion Cancer Diagnostics Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Companion Cancer Diagnostics Market Share by Type (2017-2028)
10.3 Middle East & Africa Companion Cancer Diagnostics Market Size by Application
10.3.1 Middle East & Africa Companion Cancer Diagnostics Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Companion Cancer Diagnostics Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Companion Cancer Diagnostics Market Share by Application (2017-2028)
10.4 Middle East & Africa Companion Cancer Diagnostics Market Size by Country
10.4.1 Middle East & Africa Companion Cancer Diagnostics Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Companion Cancer Diagnostics Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Company Details
11.1.2 F. Hoffmann-La Roche Business Overview
11.1.3 F. Hoffmann-La Roche Companion Cancer Diagnostics Introduction
11.1.4 F. Hoffmann-La Roche Revenue in Companion Cancer Diagnostics Business (2017-2022)
11.1.5 F. Hoffmann-La Roche Recent Developments
11.2 Agilent Technologies
11.2.1 Agilent Technologies Company Details
11.2.2 Agilent Technologies Business Overview
11.2.3 Agilent Technologies Companion Cancer Diagnostics Introduction
11.2.4 Agilent Technologies Revenue in Companion Cancer Diagnostics Business (2017-2022)
11.2.5 Agilent Technologies Recent Developments
11.3 QIAGEN
11.3.1 QIAGEN Company Details
11.3.2 QIAGEN Business Overview
11.3.3 QIAGEN Companion Cancer Diagnostics Introduction
11.3.4 QIAGEN Revenue in Companion Cancer Diagnostics Business (2017-2022)
11.3.5 QIAGEN Recent Developments
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Company Details
11.4.2 Abbott Laboratories Business Overview
11.4.3 Abbott Laboratories Companion Cancer Diagnostics Introduction
11.4.4 Abbott Laboratories Revenue in Companion Cancer Diagnostics Business (2017-2022)
11.4.5 Abbott Laboratories Recent Developments
11.5 Almac Group
11.5.1 Almac Group Company Details
11.5.2 Almac Group Business Overview
11.5.3 Almac Group Companion Cancer Diagnostics Introduction
11.5.4 Almac Group Revenue in Companion Cancer Diagnostics Business (2017-2022)
11.5.5 Almac Group Recent Developments
11.6 Danaher Corporation
11.6.1 Danaher Corporation Company Details
11.6.2 Danaher Corporation Business Overview
11.6.3 Danaher Corporation Companion Cancer Diagnostics Introduction
11.6.4 Danaher Corporation Revenue in Companion Cancer Diagnostics Business (2017-2022)
11.6.5 Danaher Corporation Recent Developments
11.7 bioM?rieuxSA
11.7.1 bioM?rieuxSA Company Details
11.7.2 bioM?rieuxSA Business Overview
11.7.3 bioM?rieuxSA Companion Cancer Diagnostics Introduction
11.7.4 bioM?rieuxSA Revenue in Companion Cancer Diagnostics Business (2017-2022)
11.7.5 bioM?rieuxSA Recent Developments
11.8 Myriad Genetics
11.8.1 Myriad Genetics Company Details
11.8.2 Myriad Genetics Business Overview
11.8.3 Myriad Genetics Companion Cancer Diagnostics Introduction
11.8.4 Myriad Genetics Revenue in Companion Cancer Diagnostics Business (2017-2022)
11.8.5 Myriad Genetics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
